BRIEF-Oruka Therapeutics Announces Ind Clearance For Everlast-A Phase 2A Trial Of Orka-001 In Psoriasis With Phase 1 Data To Be Presented At Eadv In September

Reuters
21 Jul
BRIEF-<a href="https://laohu8.com/S/ORKA">Oruka Therapeutics</a> Announces Ind Clearance For Everlast-A Phase 2A Trial Of Orka-001 In Psoriasis With Phase 1 Data To Be Presented At Eadv In September

July 21 (Reuters) - Oruka Therapeutics Inc ORKA.O:

  • ORUKA THERAPEUTICS ANNOUNCES IND CLEARANCE FOR EVERLAST-A PHASE 2A TRIAL OF ORKA-001 IN PSORIASIS WITH PHASE 1 DATA TO BE PRESENTED AT EADV IN SEPTEMBER

  • ORUKA THERAPEUTICS: IND CLEARED FOR EVERLAST-A PHASE 2A TRIAL OF ORKA-001 IN MODERATE-TO-SEVERE PSORIASIS, WITH INITIAL DATA EXPECTED 2H 2026

Source text: ID:nGNX4qSPjn

Further company coverage: ORKA.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10